Project Description

Dr. Bret A. Witter, MD, FACC, FACP

Dr. Bret A. Witter joined Los Alamitos Cardiovascular in 2003 as a partner. Dr. Witter is board certified in Echocardiography, Cardiovascular Disease and Internal Medicine (1990-2020). During the years 1996-2018, Dr. Bret Witter was an Assistant Clinical Professor at the David Geffen School of Medicine, UCLA.

Dr. Bret A. Witter’s Curriculum Vitae

Click here to download as a PDF


Cardiovascular Diseases and Echocardiography

Board Certifications and Licensure

  • Certified Echocardiography
    National Board of Echocardiography
  • Certified in Cardiovascular Disease
    American Board of Internal Medicine
    November 1993 (Recertifications: 2003 and 2013)
  • Certified in Internal Medicine
    American Board of Internal Medicine
    1990 (Recertifications: 2000 and 2009)
  • FLEX (Federal Licensing Examination)
    Part 1: 1985 | Part 2: 1986
  • National Boards (Taken Individually)
    1984 – 1987
  • NASPE Testamur (Exam)
    North American Society of Pacing and Electrophysiology

Languages Spoken

  • English
  • Medical Spanish

Current Hospital Appointments

Hospital Activities

Los Alamitos Medical Center

  • Chairman, Pharmacy and Therapeutics, 2008 – 2014

St. Mary Medical Center

  • Vice Chief of Medicine, 2002 – 2003
  • Medical Director of Cardiopulmonary Unit, 2003
  • Pharmacy and Therapeutics, 2001 – 2002
  • Cardiac Catheterization/Cardiac Surgery Committee, 1996 – 2003
  • Cardiac Catheterization/Cardiac Surgery Committee,1996 – 2000
  • CCU/ICU Committee, 1994

MemorialCare Health System
Community Hospital Long Beach

  • Chairman, Cardiac Advisory Board, 1996 – 1998

Professional Societies

  • American College of Physicians (FACP)
    Fellow: February 2002
  • American College of Cardiology (FACC)
    Fellow: May 1995
  • Los Angeles County Medical Association
    Member: 1995 – Present
  • American College of Cardiology
    Member: 1990 – Present
  • American College of Physicians
    Member: 1987 – Present

Academic Appointments

  • Assistant Clinical Professor
    David Geffen School of Medicine
    University of California, Los Angeles (UCLA)
    1996 – 2018

Work History

  • Los Alamitos Cardiovascular
    Los Alamitos, California
    October 1993 – Present
  • Cardiovascular Associates
    Long Beach, California
    July 1993 – October 1993


  • Cardiology Conference
    St. Mary Medical Center Long Beach
    2007 – Present
  • ICU Morning Report
    St. Mary Medical Center Long Beach
    1993 – 2003, 2007 – 2009
  • CCU/Cardiology Rounds
    St. Mary Medical Center Long Beach
    1993 – 2003

Professional Recognition

  • Special Recognition for Teaching Excellence
    St. Mary Medical Center  Long Beach
    2003 – 2004
  • Outstanding Teaching Physician
    St. Mary Medical Center Long Beach
    2000 – 2001
  • Outstanding Teaching Physician
    St. Mary Medical Center Long Beach
    1993 – 1994

Intramural Presentations

  • “Differentiation of Cardiac and non Cardiac chest pain.”
    CARDIOLOGY 2000 symposium at Long Beach, California Hyatt,
    May 13, 2000
  • “Transesophageal Echocardiography in the Critical care Setting.”
    CRITICAL CARE TRIAD, St. Mary Medical Center Long Beach,
    January 19, 1995


  • Witter BA, Decristofaro D. “Muscle Bands, Tendons and Trabeculations.” (Letter) Am J. Cardiol. 1992; 71:499 – 500.


  • Cardiovascular Diseases Fellowship
    St. Mary Medical Center Long Beach /Affiliated with UCLA School of Medicine
    Long Beach, California
    July 1990 – June 1993
  • Internal Medicine Residency
    St. Mary Medical Center Long Beach /Affiliated with UCLA School of Medicine
    Long Beach, California
    July 1988 – June 1990
  • Internal Medicine Internship
    St. Mary Medical Center Long Beach /Affiliated with UCLA School of Medicine
    Long Beach, California
    July 1987 –  June 1988
  • Medical Education
    Baylor College of Medicine

    Houston, Texas
    August 1983 – June 1987
  • Undergraduate Education
    Biological Sciences
    University of California, Irvine (UCI)

    Irvine, California
    September 1979 – June 1983

Education Honors and Awards

  • Phi Beta Kappa
    Magna Cum Laude
    University of California, Irvine 1983

Research Experience

  • AEGIS: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome.
    Sub-Investigator | 2019
    Sponsor: CSL Behring LLC
  • COVET : Comparison of Oral anticoagulants for extended Venous Thromboembolism (COVET). It is a randomized, open label, active comparator to determine whether the direct oral anticoagulant apixaban and rivaroxaban are safer than warfarin (fewer bleeding complications) and still as effective as warfarin (no increase in recurrent blood clots).
    Sub-Investigator | 2018 – Present
    Sponsor : Patient-Centered Outcomes Research Institute (PCORI)
  • NODE 301: Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia.
    Sub-Investigator | 2019
    Sponsor: Milestone Pharmaceuticals Inc.
  • NODE 302: Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (Extension of NODE-301).
    Sub-Investigator | 2019
    Sponsor: Milestone Pharmaceuticals Inc.
  • PARADISE MI: A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.
    Sub-Investigator | 2018 – Present
    Sponsor: Novartis
  • PEA-VALVE: Phono- and Electrocardiogram Assisted Detection of Valvular Disease. This is data collection of recorded heart sounds + ECGs using Eko Duo and Eko Core devices to further refine and validate algorithms using de-identified diagnosis confirmed by gold-standard echocardiograms.
    Sub-Investigator | 2018 – Present
    Sponsor: Eko Devices
  • GALACTIC-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
    Sub-Investigator | 2017 – Present
    Sponsor: Amgen
  • PROVE-HF: A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
    Sub-Investigator | 2017 – 2019
    Sponsor: Novartis
  • Barostim Therapy for Heart Failure (BeAT-HF): The Barostim Neo – Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
    Sub-Investigator | 2016 – Present
    Sponsor: CVRx, Inc.
  • MLHFQ Study: Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
    Sub-Investigator | 2016 – 2017
    Sponsor: Gilead/ICON
  • THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS – Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
    Sub-Investigator | 2015 – Present
    Sponsor: AstraZeneca
  • Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
    Sub-Investigator | 2015 – 2016
    Sponsor: Amgen, Evidera
  • DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
    Sub-Investigator | 2013 – 2018
    Sponsor: AstraZeneca
  • ODYSSEY EFC11570: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
    Sub-Investigator | 2013 – 2017
    Sponsor: Sanofi
  • SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.
    Sub-Investigator | 2013 – 2017
    Sponsor: Yale University School of Medicine/NIH
  • RivaroxAFL3003: An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
    Sub-Investigator | 2013– 2014
    Sponsor:  Janssen Scientific Affairs/Johnson & Johnson
  • Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.
    Sub-Investigator | 2013
    Sponsor: Tasly Pharmaceuticals
  • Cardiovascular Inflammation Reduction Trial (CIRT): Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
    Sub-Investigator | 2013 – 2018
    Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute
  • User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2 PT/INR Monitoring System (ADAPT) BSTE-0159.
    Sub-Investigator | 2012
    Sponsor: Alere San Diego
  • Mission® PT Coagulation Monitoring System Clinical Study.
    Principal Investigator | 2012
    Sponsor: ACON Laboratories, INC
  • The “BRIDGE” Trial (1U01HL08675501A1): Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
    Sub-Investigator | 2012 – 2015
    Sponsor: National Institutes of Health (NIH)-National Heart, Lung and Blood Institute (NHLBI)
  • GLORIA-AF 1160.129: Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
    Sub-Investigator | 2012 – Present
    Sponsor: Boehringer Ingelheim
  • BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.
    Sub-Investigator | 2010 – 2012
    Sponsor: St. Jude Medical Center
  • The PROMISE Trial: PROspective Multicenter Imaging Study for Evaluation of Chest Pain.
    Sub-Investigator | 2010 – 2014
    Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
  • ORBIT-AF I and II: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
    Sub-Investigator | 2010 – 2017
    Sponsor: Janssen Scientific Affairs, LLC
    Collaborator: Duke Clinical Research
    NCT01165710 & NCT01701817
  • RATE: Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
    Principal Investigator | 2008 – 2010
    Sponsor: St. Jude Medical Center
  • FREEDOM: A Frequent Optimization Study the Quick Opt ™ Method.
    Sub-Investigator | 2008 – 2010
    Sponsor: St. Jude Medical Center
  • SAFE (Silent Atrial Fibrillation Detection with Stored EGMS).
    Sponsor: Guidant Corporation
  • ENGAGE: Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation – Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE – AF TIMI – 48).
    Sub-Investigator | 2009 – 2015
    Sponsor: Daiichi Sankyo Pharma Development
  • Fosiniopril Drug Study.
    Sub-Investigator | 1992
    Sponsor: Bristol- Myers Squibb Company
  • Supine Bike/Stress Echo (Unpublished).
    A.S. Abbasi, MD, FACC
    Long Beach, California
  • Molecular Biology/ Immunology Cell Culture, electrophoresis techniques, 1978 – 1979. Gale Granger, PhD
    University of California, Irvine